ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention

NCT ID: NCT06535139

Last Updated: 2025-09-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

4630 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-09

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are three main objectives of the protocol. First, we will evaluate the added clinical- and cost- effectiveness of parent-targeted motivational aids (reminder/recall and phone-based MI) alone and when combined with community-targeted healthcare access assistance beyond the effects of clinician-targeted training. Second, we will estimate the differential effectiveness of the implementation strategies by patient-level factors (age, race/ethnicity, sex, distance from home to clinic, social vulnerability). Third, we will measure moderation of implementation strategy effectiveness by clinic-level factors (HPV vaccination priority, resources, clinic visit types, scheduling practices, and implementation success).

Within 11 rural North Central Florida counties, we will evaluate the layering of evidence-based implementation strategies that progressively addressing clinician, parent, and healthcare access barriers faced by rural communities on HPV vaccination rates among 9- to 12-year-olds. To best address our main question of whether layering complementary strategies continues to increase effects on HPV vaccination, we will test our hypotheses with a three-arm cluster randomized study design of nested strategies. The proposed nested study design optimizes evaluation, causal inference, and scientific rigor by putting the maximum number of clinics towards addressing the layering of strategies. Randomization will occur at the clinic level. All clinics will receive implementation strategy A: clinician-targeted recommendation training. A random 20 of 30 of clinics will also receive facilitation of parent-targeted motivational aids (B) for an implementation strategy package of A+B. Finally, a random half of the clinics who receive A+B will also receive community-targeted healthcare access (C) for a total implementation strategy package of A+B+C. This equates to a three-arm cluster randomized trial in which 10 clinics receive clinician- targeted recommendation training alone (A), 10 clinics receive clinician-targeted recommendation training and parent-targeted motivational aids (A+B), and 10 clinics receive clinician-targeted recommendation training, parent-targeted motivational aids, and community-targeted healthcare access (A+B+C).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are three main objectives of the protocol. First, we will evaluate the added clinical- and cost-effectiveness of parent-targeted motivational aids (reminder/recall and phone-based MI) alone and when combined with community-targeted healthcare access assistance beyond the effects of clinician-targeted training. Second, we will estimate the differential effectiveness of the implementation strategies by patient-level factors (age, race/ethnicity, sex, distance from home to clinic, social vulnerability). Third, we will measure moderation of implementation strategy effectiveness by clinic-level factors (HPV vaccination priority, resources, clinic visit types, scheduling practices, and implementation success).

We propose a multilevel approach, incorporating evidence-based strategies that address clinicians' recommendations, parents' hesitations, and access to healthcare is needed to reduce the HPV-related cancer disparities in rural areas. Within 11 rural North Central Florida counties, we will adapt, implement, and evaluate the layering of evidence-based implementation strategies by progressively addressing clinician, parent, and healthcare access barriers faced by rural communities on HPV vaccination rates among 9- to 12-year-olds. To increase reproducibility, we propose a conceptual framework, specified implementation strategies, randomization, adaptive and sequential implementation strategies, process and outcome measures, appropriate statistical analysis, and conservative power calculations.

To best address our main question of whether layering complementary strategies continues to increase effects on HPV vaccination, we will test our hypotheses with a three-arm cluster randomized study design of nested strategies. The proposed nested study design optimizes evaluation, causal inference, and scientific rigor by putting the maximum number of clinics towards addressing the layering of strategies. Randomization will occur at the clinic level. All clinics will receive implementation strategy A: clinician-targeted recommendation training. A random 20 of 30 of clinics will also receive facilitation of parent-targeted motivational aids (B) for an implementation strategy package of A+B. Finally, a random half of the clinics who receive A+B will also receive community-targeted healthcare access (C) for a total implementation strategy package of A+B+C. This equates to a three-arm cluster randomized trial in which 10 clinics receive clinician-targeted recommendation training alone (A), 10 clinics receive clinician-targeted recommendation training and parent-targeted motivational aids (A+B), and 10 clinics receive clinician-targeted recommendation training, parent-targeted motivational aids, and community-targeted healthcare access (A+B+C).

Random Assignment:

Clinics will be randomized into three equal arms. Ten clinics will receive clinician-targeted recommendation training alone (A). Ten clinics will receive clinician-targeted recommendation training and parent-targeted motivational aids (A+B). Ten clinics will receive clinician-targeted recommendation training, parent-targeted motivational aids, and community-targeted healthcare access (A+B+C).

Delivery of interventions:

As delivery of interventions is conducted at the clinic level and all interventions are evidence-based, these interventions will be conducted as quality improvement.

Clinician-targeted Recommendation Training. All participating clinicians and nurses at all 30 participating clinics will be offered trainings via a one-hour Zoom video conference. Structured after and intending to enhance and expand the NCI Evidence-based Program by focusing on empathy as central to the conversation and including 9- to 10-year-olds who are not eligible for Tetanus, Diphtheria, and Pertussis or Meningitis ACWY, Drs. Staras (PI), Thompson, and Bylund developed and have conducted preliminary testing of the C-LEAR (Counsel, Listen, Empathize, Answer, Recommend) training as part of our R37 (Staras PI) (Section C.2.2). C-LEAR incorporates concepts from Motivational Interviewing, facework theories, and patient-centered communication.

Parent-targeted Motivational Aids. Twenty of the 30 clinics will be offered the parent-targeted motivational aids implementation strategy which includes reminder/recall and parent-targeted phone- based MI.

Reminder/Recall. We will facilitate clinic staff sending these customized reminder/recall messages via one of three methods (postcards, text messages, or phone calls) to increase clinic adaptability to existing services and workflow. We will assist clinics in identifying 9- to 12-year-olds who have not received the HPV vaccine though the Florida state immunization registry and their EHR systems. Reminder/recall for initiation and follow-up doses will be sent at three meaningful milestones:

(1) two weeks before an adolescent's birthday, (2) two weeks prior to fall school start, and (3) within the first weeks of January.

Parent-targeted Phone-based MI. Following our previously feasible and acceptable process for phone-based MI, parents who have been sent at least two reminder/recall messages for initiation or follow-up without response (contact or clinic visit) after one month will be eligible for phone-based MI. Based on our pilot study, we anticipate MI sessions will last approximately ten minutes.

Community-targeted Healthcare Access. We will address social determinants faced by families living in rural areas in three ways: (1) linking patients to transportation assistance, (2) providing a mobile vaccination clinic, and (3) linking patients to health insurance navigators. The activities will be managed by the UF Health Cancer Center's Community Outreach and Engagement Community Navigation office as these services are consistent with their current offerings. UF Pediatrics and UF CTSI will offer mobile vaccine clinics as part of standard of care 40 times during the intervention period (4 times for each of the 10 assigned clinics). The mobile vaccination clinics will offer all adolescent vaccines (HPV, Tetanus, Diphtheria, and Pertussis, Meningitis ACWY, Influenza - in season, and COVID-19). Adolescents will receive the vaccines free of charge: billed to insurance or the Federal Vaccines for Children Program which covers vaccines for all children 18 years and under who are eligible for Medicaid or are uninsured, underinsured, or Native American or Alaskan Native. All administered vaccines will be reported to the Florida immunization registry, and, thus discoverable by clinics statewide including participating clinics.

Statistical Analysis and Design:

We will randomize 30 participating clinics to three arms (10 clinics per study arm). We will use constrained randomization to reduce imbalance among a priori determined confounders (i.e., baseline vaccination rate). The statistical team will be blinded to study arm assignments.

Clinical Effectiveness Analysis. The proposed group randomized trial consists of clustered data with patients nested within clinics. Any statistical analysis that ignores lack of independence due to nesting will be subject to inflated type-1 errors. To account for the clinic level clustering effect, intervention effects on HPV vaccine initiation will be estimated with generalized linear mixed models. We describe briefly our general strategy for specifying both the covariance and mean models for proposed analyses in Aims 1 through 3.

In this trial, cluster sampling generates exchangeable observations, and therefore compound symmetric covariance for patients nested within clinics is appropriate. Implementing the covariance model can be done for our binary outcome (HPV vaccine initiation) in PROC GLIMMIX in SAS by specifying a random intercept for clinic. In addition to efficiently accounting for non-independence, a generalized linear mixed model approach provides the flexibility to specify different link and variance functions based. Our primary specification will be a log() link and binomial variance to directly estimate the risk ratio. Should model convergence issues arise, we will estimate a logit model on the odds scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Papillomavirus Vaccines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

We will test our hypotheses with a three-arm cluster randomized study design of nested strategies. Randomization will occur at the clinic level. All clinics will receive implementation strategy A: clinician-targeted recommendation training. A random 20 of 30 of clinics will also receive facilitation of parent-targeted motivational aids (B) for an implementation strategy package of A+B. Finally, a random half of the clinics who receive A+B will also receive community-targeted healthcare access (C) for a total implementation strategy package of A+B+C. This equates to a three-arm cluster randomized trial in which 10 clinics receive clinician- targeted recommendation training alone (A), 10 clinics receive clinician-targeted recommendation training and parent-targeted motivational aids (A+B), and 10 clinics receive clinician-targeted recommendation training, parent-targeted motivational aids, and community-targeted healthcare access (A+B+C).
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clinician-targeted training

All clinicians and nurses will be assigned to participate in a training on how to recommend or discuss the HPV vaccine.

Group Type EXPERIMENTAL

Brief training

Intervention Type BEHAVIORAL

Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.

Clinician-targeted training and Parent-targeted motivational aids

All clinicians and nurses will be assigned to participate in a training on how to recommend or discuss the HPV vaccine. Also, clinics will send reminder/recall messages to parents about the HPV vaccine and offer phone-based motivational interviews.

Group Type EXPERIMENTAL

Brief training

Intervention Type BEHAVIORAL

Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.

Parent-targeted motivational aids

Intervention Type BEHAVIORAL

Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.

Clinician-targeted training, Parent-targeted motivational aids, and Healthcare Access

All clinicians and nurses will be assigned to participate in a training on how to recommend or discuss the HPV vaccine. Also, clinics will send reminder/recall messages to parents about the HPV vaccine and offer phone-based motivational interviews. Plus, clinics will have access to healthcare access assistance.

Group Type EXPERIMENTAL

Brief training

Intervention Type BEHAVIORAL

Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.

Parent-targeted motivational aids

Intervention Type BEHAVIORAL

Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.

Healthcare access

Intervention Type BEHAVIORAL

Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brief training

Clinicians and nurses will receive a brief training. Each training will have a one-hour didactic and interactive session and follow-up practice sessions. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 9- to 12-years of age, and prevents cancer.

Intervention Type BEHAVIORAL

Parent-targeted motivational aids

Parents will be sent messages via text, phone, or postcard about the HPV vaccine. Parents who do not respond to messages will be offered a phone-based motivational interview session about the HPV vaccine.

Intervention Type BEHAVIORAL

Healthcare access

Healthcare access will involve three components coordinated by UF Health Cancer Center Community Outreach and Engagement Office: transportation assistance to a participating clinic or mobile vaccination clinic, UF mobile vaccination clinic scheduling, and connection to health insurance navigators.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adolescents Age 8- to 12-years-old Visited participating clinic in past year or during study No records of receiving both HPV vaccine doses
* Providers Provide 9- to 12-year-old patients primary care Practice at a participating clinic

Exclusion Criteria

* Adolescents Out of age range
* Providers Unwilling to consent
Minimum Eligible Age

8 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephanie Staras, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida

Gainesville, Florida, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stephanie Staras, PhD

Role: CONTACT

352-294-8299

Marta Hansen, MBA

Role: CONTACT

352-627-9075

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01CA268014

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB202301601

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.